In relapsed small-cell lung cancer after platinum therapy, the B7-H3 antibody-drug conjugate tambotatug pelitecan beat topotecan on overall survival at interim analysis (median 13.3 vs 9.4 months; HR 0.46), with fewer grade ≥3 adverse events (55.4% vs 77.9%).
RCTn = 451
Zhao et al. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy